- Home
- FISI vs ALT Comparison
FISI vs ALT Comparison
Compare FISI & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FISI | ALT |
|---|---|---|
| Founded | 1817 | 1997 |
| Country | United States | United States |
| Employees | 598 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.4M | 415.3M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | FISI | ALT |
|---|---|---|
| Price | $30.13 | $3.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $35.33 | $15.50 |
| AVG Volume (30 Days) | 130.7K | ★ 2.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.22 | $756,308.50 |
| P/E Ratio | $9.36 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $20.97 | $2.91 |
| 52 Week High | $35.47 | $7.73 |
Technical Indicators
Market Signals| Indicator | FISI | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 32.29 | 35.12 |
| Support Level | $25.17 | $3.39 |
| Resistance Level | $33.04 | $4.25 |
| Average True Range (ATR) | 1.05 | 0.24 |
| MACD | -0.27 | -0.06 |
| Stochastic Oscillator | 13.74 | 15.24 |
Price Performance
Historical ComparisonAbout FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.